These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


144 related items for PubMed ID: 17637558

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G, Wilmink JW.
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hand and foot syndrome secondary to capecitabine.
    Lal HS.
    Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
    [Abstract] [Full Text] [Related]

  • 8. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
    Villalón G, Martín JM, Pinazo MI, Calduch L, Alonso V, Jordá E.
    Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H.
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita G, Díaz-Rubio E, Benítez J, González-Neira A.
    Clin Cancer Res; 2011 Apr 01; 17(7):2006-13. PubMed ID: 21325291
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
    Akahane T, Chiba T, Yano H, Hashimoto Y.
    Gan To Kagaku Ryoho; 2007 Mar 01; 34(3):435-8. PubMed ID: 17353638
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High frequency of hand foot syndrome with capecitabine.
    Kamil M, Haron M, Yosuff N, Khalid I, Azman N.
    J Coll Physicians Surg Pak; 2010 Jun 01; 20(6):421-2. PubMed ID: 20642979
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.